[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platelets\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platelets":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,77,102,131],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100527420",false,"NCT06147531","Delayed Cold-Stored Platelets -PLTS-1","A Clinical Comparison of Cold-stored and Room Temperature-stored Allogeneic Platelet Transfusions in Bleeding Adult Cardiac Surgery Patients - A Randomized Multicentre Pilot Study (PLTS-1 Study)","PLTS-1","Inclusion Criteria:\n\nAdult (≥18 years old) patients undergoing elective cardiac surgery with CPB will be eligible for inclusion if they are planned to undergo at least moderately complex surgery or have a preoperative platelet count ≤150,000 x106\u002FL (this is a group at high risk of requiring platelet transfusions post-CPB).\n\nModerately complex index surgery is defined as:\n\n1. repair\u002Freplacement of more than one valve;\n2. aorta (root\u002Fascending\u002Farch) replacement;\n3. any combination of coronary artery bypass grafting, valve repair\u002Freplacement, or aorta (root\u002Fascending\u002Farch) replacement; or\n4. re-do procedures consisting of a repair or revision of a prior cardiac intervention.\n\nExclusion Criteria:\n\nPatients will be excluded if cold-stored platelets are not going to be available at the time of surgery or if the patient:\n\n1. has a congenital or acquired hemostatic disorder (including platelet refractoriness due to anti-platelet and anti-human leukocyte antigen \\[HLA\\] antibodies) and\u002For requires specially matched platelets (including patients with anaphylaxis to blood due to Immunoglobulin A \\[IgA\\] deficiency),\n2. has known contraindications to heparin, thereby excluding cases where non-reversible anticoagulants (i.e. argatroban) are used,\n3. is on warfarin or direct oral anticoagulants (dabigatran, rivaroxaban, apixaban or edoxaban) within 3 days prior to surgery,\n4. is on antiplatelet drugs within 5 days prior to surgery (excluding acetylsalicylic acid \\[ASA\\]),\n5. refuses allogeneic blood products,\n6. has a known pregnancy,\n7. has already enrolled in this study,\n8. is enrolled in another interventional clinical trial where routine care and management are altered,\n9. has hemodynamic instability defined as critical care admission, vasopressor, or inotrope dependence prior to index surgery, or\n10. has pre-operative requirement for, or expected post-operative dependence upon mechanical circulatory support (i.e., intra-aortic balloon pump, ventricular assist device).","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","PLTS-1 is a multicentre, randomized, controlled, pilot trial, using a conventional, parallel group, two-armed design at 2 cardiac surgery centres in Canada. The study is designed to assess the feasibility of a future, definitive RCT to determine the non-inferiority of cold-stored platelets compared to conventional platelets with respect to hemostatic effectiveness (total number of allogeneic blood products transfused within 24 hours after CPB), as well as safety.",[26,27,28,29],"Platelets","Bleeding","Cardiopulmonary Bypass","Cardiac Surgery",[31,32,33,34],"Blood Platelets","Cardiac surgical procedure","Blood Preservation\u002FMethods","Blood Preservation\u002FAdverse Effects","RECRUITING","2025-12-22",{"date":38,"type":39},"2025-12-29","ACTUAL",{"date":41,"type":39},"2024-06-05",{"date":43,"type":20},"2026-12",{"name":45,"class":46},"University Health Network, Toronto","OTHER",2,{"id":49,"slug":50,"hasResults":10,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100608381","neutrophils-to-lymphocytes-and-platelets-ratio-procalcitonin-and-total-leucocytic-count-as-indicators-of-prognostic-outcome-in-septic-patients-in-the-intensive-care-unit-100608381","NCT07200817","Neutrophils to Lymphocytes and Platelets Ratio, Procalcitonin, and Total Leucocytic Count as Indicators of Prognostic Outcome in Septic Patients in the Intensive Care Unit.","Comparison Between Neutrophils to Lymphocytes and Platelets Ratio, Procalcitonin, and Total Leucocytic Count as Indicators of Prognostic Outcome in Septic Patients in the Intensive Care Unit.","Inclusion Criteria:\n\n* Age from 18 to 70 years old.\n* Both sexes.\n* Septic patients (under the third international consensus definitions of sepsis and septic shock).\n\nExclusion Criteria:\n\n* Pregnancy\n* Malignancy\n* On immunosuppressive therapy\n* Hematological Disorders\n* Major Trauma\n* Major Burns\n* Child-Pugh Class C Liver Cirrhosis\n* On Hemodialysis","70 Years",{"count":57,"type":20},290,"OBSERVATIONAL","This study aims to compare Neutrophil to Lymphocyte and Platelet Ratio, Procalcitonin, and Total Leucocyte Count as indicators of prognostic outcome in septic patients in the intensive care unit.",[61,26,62,63,64,65,66],"Neutrophils to Lymphocytes","Procalcitonin","Total Leucocytic Count","Prognostic Outcome","Septic Patients","Intensive Care Unit","2025-09-23",{"date":69,"type":39},"2025-10-01",{"date":71,"type":39},"2024-09-20",{"date":73,"type":20},"2026-03-19",{"name":75,"class":46},"Ain Shams University",1,{"id":78,"slug":79,"hasResults":10,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":76},"100597935","phase-2-autologous-cold-stored-apheresis-platelets-100597935","NCT07064954","Autologous Cold-stored Apheresis Platelets","Auto-PLTS: The Effectiveness of Autologous, Cold-stored Platelets Collected 7-10 Days Before Cardiac Surgery for Avoidance of Allogeneic Transfusions: A Randomized Patient Preference Trial","Auto-PLTS","Inclusion Criteria:\n\nAdult (≥18 years old) patients who meet all following criteria:\n\n1\\. Undergoing elective complex cardiac surgery consisting of at least one of the following:\n\n* Repair or replacement of more than one valve (i.e., multiple valves)\n* Repair or replacement of any segment of aortic arch\n* At least two of any combination of coronary artery bypass grafting (CABG), valve repair\u002Freplacement, or aorta (ascending\u002Farch) repair\u002Freplacement\n* Complex adult congenital repair\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria are not eligible for the study:\n\n1. Seven days or less from recruitment to surgery (as there will not be sufficient time from platelet donation to surgery for patients to recover their platelet count)\n2. Patient factors that preclude platelet donation or increase risk of adverse events after donation, including any of the following:\n\n   * Poor intravenous access\n   * Low baseline platelet count (≤150,000 x106\u002FL)\n   * Low baseline hemoglobin (\\\u003C100 g\u002FL) (since approximately 50 mL of red blood cells are lost with each unit of apheresis platelet collection)\n   * Inability to tolerate fluid shifts during donation (i.e., severe aortic stenosis with valve area \\\u003C0.7 cm2, or left main coronary artery stenosis \\>80%, or left ventricular ejection fraction \\\u003C30%)\n   * Increased risk of bacterial contamination of collected units (i.e., active infection, on antibiotics, dental procedure \\\u003C72 hours before donation)\n   * Attending clinicians deem the patient ineligible for autologous predonation\n   * Known positivity for active infectious blood-borne disease (HIV, HCV, HBV, HTLV, Syphilis)\n3. Highly specialized procedures such as insertion or removal of ventricular assist devices or repair of thoracoabdominal aneurysm\n4. Any history of congenital or acquired bleeding disorder (including any type of thrombocytopenia or platelet refractoriness due to anti-platelet and anti-HLA antibodies or requirement for specially matched platelets)\n5. On any anticoagulant or antiplatelet medications, excluding ASA, that cannot be stopped at least 7 days before donation (72 hours for NSAIDs)\n6. Refusal of allogeneic blood products due to religious or other reasons\n7. Known or suspected pregnancy",{"count":86,"type":20},100,[23,88],"PHASE3","The Auto-PLTS Study is a single-centre trial performed at Toronto General Hospital (TGH) that uses a randomized, patient preference design. The recent introduction of cold-stored platelets with a shelf-life of 14 days into clinical practice has made it possible to offer autologous apheresis platelet predonation to patients undergoing elective cardiac (and other high-blood-loss) surgeries while allowing sufficient time to recover platelet count before surgery. The Auto-PLTS Study is designed to assess whether replacing allogeneic platelets with autologous platelets will improve patient outcomes and benefit the healthcare system by reducing the burden on allogeneic platelet supply. The study is also designed to determine whether patients are willing to donate autologous platelets 7-10 days prior to surgery.",[27,26,28,29],[92],"Autologous Blood Donation","NOT_YET_RECRUITING","2025-07-17",{"date":96,"type":39},"2025-07-22",{"date":98,"type":20},"2025-09-01",{"date":100,"type":20},"2027-04-30",{"name":45,"class":46},{"id":103,"slug":104,"hasResults":10,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":113,"conditions":114,"keywords":121,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":76},"100518650","characterization-and-quantification-of-plateletleukocyte-aggregates-in-patients-with-suspected-heparin-induced-thrombocytopenia-100518650","NCT06033300","Characterization and Quantification of Platelet\u002FLeukocyte Aggregates in Patients With Suspected Heparin-induced Thrombocytopenia","HITSTREAM","Inclusion Criteria:\n\n* Age \\> 18 years\n* Any adult patient suspected of having HIT, with a positive anti-PF4\u002FH antibody test\n* Patient signed consent to study participation\n* Patient with social security coverage\n\nExclusion Criteria:\n\n* All adult patients with suspected HIT and negative anti-PF4\u002FH antibody test.\n* Protected adults (guardianship, under curators) or deprived of liberty",{"count":110,"type":20},200,[112],"NA","The investigators would like to analyze platelet\u002Fleukoplak activation, quantify and morphologically characterize these aggregates using in vitro analysis, directly on whole blood from adult patients with suspected HIT. This would enable to better describe the in vivo pathophysiology of the HIT-suspect patient, and eliminate the need for platelet donors to perform the usual confirmatory techniques, whose inter- and intra-individual variability is very high. What's more, the SRA test, evaluated as the reference test, requires the use of radioisotopes and is therefore only carried out in a few biological expertise centers, resulting in a very long delay in the delivery of results. It should also be noted that, in practice, HÉPARINE is immediately stopped in patients with suspected HIT, and they are put on an expensive anticoagulant (DANAPAROIDE SODIQUE or ARGATROBAN) in curative doses until the results of the confirmatory tests are back. In this serious, life-threatening condition, it is essential to have a sensitive, specific test to confirm HIT as quickly as possible. Each patient with suspected HIT (rapid \\>30% reduction in platelet count after initiation of heparin therapy) should have 4 tubes of 3.2% citrated whole blood (2.7ml) collected at the time of suspected HIT (D0) and before any therapeutic switch (or 24 h max after switch). A new sample (4 citrated tubes) will be taken at D4, D7 and D14 during hospitalization, in patients who test positive for anti-PF4\u002FH Ac. All patients with suspected HIT will follow the standard diagnostic pathway, i.e. a screening test (immunological test for anti-PF4\u002Fheparin antibodies, total Ig, ACL TOP, Werfen) followed by a confirmatory test (platelet aggregation on TA-8V, STAGO and\u002For SRA). Doppler ultrasonography of the lower limbs will be performed in HIT-suspect patients with a positive anti-PF4\u002FH antibody test, as currently performed as part of routine care.",[115,116,117,26,118,119,107,120],"Heparin-induced Thrombocytopenia","HIT","Platelet Activation","Leukocytes","Platelet\u002FLeukocyte Aggregates","Flow Cytometry",[115],"2025-05-21",{"date":124,"type":39},"2025-05-25",{"date":126,"type":39},"2023-04-17",{"date":128,"type":20},"2026-04",{"name":130,"class":46},"Centre Hospitalier Universitaire, Amiens",{"id":132,"slug":133,"hasResults":10,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":140,"studyType":58,"phases":4,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":76},"100564448","platelet-and-autotransfusion-device-in-cardiac-surgery-100564448","NCT06629311","Platelet and Autotransfusion Device in Cardiac Surgery","Study of Platelet Count Changes During the Use of Autotransfusion Device in Cardiac Surgery","PLAQ-SES","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Having undergone standard cardiac surgery (excluding redux surgery, dissection, endocarditis, circulatory assist and transplants)\n* Treated with an autotransfusion device during the surgery\n* Subject having expressed their consent to the study\n\nExclusion Criteria:\n\n* Anemia less than 7 g\u002FdL\n* Pregnant women\n* Redux surgery, dissection, endocarditis, circulatory assistance, and transplants\n* Contraindication to the use of an autotransfusion device\n* Impossibility of giving the subject informed information",{"count":86,"type":20},"32 Days","Cardiac surgery is a bleeding-risk surgery and frequently requires blood transfusion. Intraoperative autotransfusion devices are used to aspirate, process and retransfuse patients' blood. These devices are effective in recovering red blood cells and limiting the need for transfusion of packed red blood cells. Some devices, such as I-SEP's SAME®, can also be used to recover platelets, but their effectiveness has not yet been evaluated in real-life situations. The aim of this study is therefore to investigate the evolution of platelet counts following the use of an intraoperative recovery device in adult patients undergoing standard cardiac surgery",[26,143],"Autotransfusion Device",[145,146,26],"Cardiac surgery","Autotransfusion device","2025-03-31",{"date":149,"type":39},"2025-04-03",{"date":151,"type":39},"2025-02-04",{"date":153,"type":20},"2026-09-08",{"name":155,"class":46},"University Hospital, Strasbourg, France"]